Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay

While proteasome inhibition is a validated therapeutic approach for multiple myeloma (MM), inhibition of individual constitutive proteasome (c20S) and immunoproteasome (i20S) subunits has not been fully explored owing to a lack of effective tools. We utilized the novel proteasome constitutive/immuno...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Br J Haematol
Main Authors: Lee, Susan J., Levitsky, Konstantin, Parlati, Francesco, Bennett, Mark K., Arastu‐Kapur, Shirin, Kellerman, Lois, Woo, Tina F., Wong, Alvin F., Papadopoulos, Kyriakos P., Niesvizky, Ruben, Badros, Ashraf Z., Vij, Ravi, Jagannath, Sundar, Siegel, David, Wang, Michael, Ahmann, Gregory J., Kirk, Christopher J.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2016
Teme:
Haematological Malignancy
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5074317/
https://ncbi.nlm.nih.gov/pubmed/27071340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14014
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki